Sulaiman Al Habib profit jumps 20% in 2022 to SAR 1.65 bln; Q4 at SAR 441.5 mln
Dr. Sulaiman Al Habib Medical Services Group (HMG) posted a 20% rise in net profit after Zakat and tax to SAR 1.65 billion for 2022, compared to SAR 1.37 billion in 2021.
Financials (M)
Item | 2021 | 2022 | Change |
---|---|---|---|
Revenues | 7,250.47 | 8,310.74 | 14.6 % |
Gross Income | 2,330.23 | 2,748.14 | 17.9 % |
Operating Income | 1,466.15 | 1,700.49 | 16.0 % |
Net Income | 1,376.62 | 1,650.75 | 19.9 % |
Average Shares | 350.00 | 350.00 | - |
EPS (Riyals) | 3.93 | 4.72 | 19.9 % |
The higher profit was spurred by revenues, which increased by 14.62% year-on-year (YoY) to SAR 83.10 billion, on growth in all segments.
The annual revenue growth was mainly driven by the hospital segment, due to the increase in the number of patients and higher occupancy for inpatient. The pharmacy segment sales also rose, driven by a rise in the number of patients compared to the previous year.
Earnings before interest, tax, depreciation and amortization (EBITDA) jumped 15.66% YoY to SAR 2.13 billion, driving EBITDA margin to reach 25.70% compared to 25.47% in 2021.
Current Quarter Comparison (M)
Item | Q4 2021 | Q4 2022 | Change |
---|---|---|---|
Revenues | 1,968.13 | 2,253.68 | 14.5 % |
Gross Income | 643.38 | 737.07 | 14.6 % |
Operating Income | 396.25 | 427.56 | 7.9 % |
Net Income | 383.59 | 441.50 | 15.1 % |
Average Shares | 350.00 | 350.00 | - |
EPS (Riyals) | 1.10 | 1.26 | 15.1 % |
The fourth-quarter net profit grew by 15% to SAR 441.5 million, from SAR 383.59 million in the prior-year period.
Compared to the previous quarter, net profit rose 5% from SAR 420.62 million.
Shareholders’ equity, no minority interest, rose to SAR 5.87 billion as of Dec. 31, 2022, from SAR 5.33 billion a year earlier.
View other reports
Share Price
Dr. Sulaiman Al Habib Medical Services Group (SULAIMAN ALHABIB)
Current | |
Market Cap (M Riyal) | 98,700.00 |
Enterprise Value (EV) (M) | 103,668.80 |
Shares Outstanding ((M)) | 350.00 |
EPS ( Riyal) (TTM) | 6.36 |
Book Value (BV) ( Riyal) | 19.97 |
Par Value ( Riyal) | 10.00 |
Adjusted P/E (Last12) | 45.51 |
P/E (TTM) | 44.33 |
Price/book | 14.12 |
Return on Average Assets (%) (TTM) | 13.0 |
Return on Average Equity (%) (TTM) | 33.3 |
Financial results (Million)
Period | Revenues | Change | Gross Income | Change | Operating Income | Change |
---|---|---|---|---|---|---|
Q1 2022 | 1,990.86 | 17.5 % | 658.56 | 19.9 % | 422.09 | 20.7 % |
Q2 2022 | 2,014.01 | 15.0 % | 670.88 | 21.8 % | 414.75 | 22.1 % |
Q3 2022 | 2,052.19 | 11.8 % | 681.63 | 16.2 % | 436.09 | 14.6 % |
Q4 2022 | 2,253.68 | 14.5 % | 737.07 | 14.6 % | 427.56 | 7.9 % |
2022 | 8,310.74 | 14.6 % | 2,748.14 | 17.9 % | 1,700.49 | 16.0 % |
Profit Performance (Million)
Period | Net Income | Change | EPS(Riyal) | Extraordinary Income/Expense | Net Profit Before Unusual Items | EPS Before XO Items |
---|---|---|---|---|---|---|
Q1 2022 | 390.51 | 22.4 % | 1.12 | - | 390.51 | 1.12 |
Q2 2022 | 398.13 | 22.4 % | 1.14 | - | 398.13 | 1.14 |
Q3 2022 | 420.62 | 20.7 % | 1.20 | - | 420.62 | 1.20 |
Q4 2022 | 441.50 | 15.1 % | 1.26 | - | 441.50 | 1.26 |
2022 | 1,650.75 | 19.9 % | 4.72 | - | 1,650.75 | 4.72 |
Profitability
Period | Gross Margin | OIBDA Margin | Net Margin Before Unusual Items |
---|---|---|---|
Q1 2022 | 32.32 % | 24.53 % | 19.19 % |
Q2 2022 | 32.77 % | 24.65 % | 19.47 % |
Q3 2022 | 33.08 % | 24.69 % | 19.85 % |
Q4 2022 | 33.07 % | 24.18 % | 19.86 % |
2022 | 33.07 % | 24.18 % | 19.86 % |
Per Share Data (Riyal)
Period | Shares Outstanding (M) | EPS (Riyal) | Adjusted EPS (Riyal) | Book Value (BV) |
---|---|---|---|---|
Q1 2022 | 350.00 | 4.14 | 4.14 | 15.67 |
Q2 2022 | 350.00 | 4.35 | 4.35 | 15.98 |
Q3 2022 | 350.00 | 4.55 | 4.55 | 16.32 |
Q4 2022 | 350.00 | 4.72 | 4.72 | 16.80 |
Multiple Ratios (End of Period Price)
Period | P/E | Adjusted P/E | Price/book |
---|---|---|---|
Q1 2022 | 46.02 | 46.02 | 12.15 |
Q2 2022 | 44.60 | 44.60 | 12.13 |
Q3 2022 | 45.70 | 45.70 | 12.74 |
Q4 2022 | 46.77 | 46.77 | 13.13 |
Business Segments (Million)
Q4 2022
Period | Hospitals | Pharmacies | Others |
---|---|---|---|
Q1 2022 | 1,506.00 | 417.00 | 68.00 |
Q2 2022 | 1,534.00 | 407.00 | 73.00 |
Q3 2022 | 1,557.00 | 408.00 | 87.00 |
Q4 2022 | 1,701.00 | 492.00 | 61.00 |
Analysts Estimates (Million)
Item | Q4 2022 (e) | Q4 2022 (a) | Change |
---|---|---|---|
Average | 443.48 | 441.50 | (0.4 %) |
Estimates vs Actual (Million)
Item | Q4 2022 (e) | Q4 2022 (a) | Change |
---|---|---|---|
SNB Capital | 441.00 | 441.50 | 0.1 % |
OSOOL AND BAKHEET | 442.03 | 441.50 | (0.1) % |
AlJazira Capital | 442.50 | 441.50 | (0.2) % |
Al Rajhi Capital | 440.00 | 441.50 | 0.3 % |
Sico | 445.00 | 441.50 | (0.8) % |
Riyad Capital | 447.00 | 441.50 | (1.2) % |
U-Capital | 424.30 | 441.50 | 4.1 % |
Hermes | 466.00 | 441.50 | (5.3) % |
Comments {{getCommentCount()}}
Be the first to comment
رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}
{{comment.DisplayName}}
{{comment.ElapsedTime}}